Side by side
Consultation participation and their own register declarations, side by side. Counts, not judgments — participation is not influence.
Counts here are a floor, never a total: they cover the 583 consultation files tracked so far (42,224 submissions, mostly 2025–26), so an organization's real filing history is larger, not smaller.
Trade union · France
Industry association · Italy
Declared costs: €900K+ a year · in the register since 2009
Compulsory licensing of patents in crisis situations · Supplementary protection certificate for plant protection products. Recast
Register facts self-declared (snapshot 2 Sept 2026); cost bands are floors. Shared files are shared attention, not evidence of coordination.
Their opening passages on the files they share, verbatim and in filing order. We do not summarize, compare, or characterize positions — read them at source.
Leem · filed 29 Apr 2022 · source
The substantial investment in R&D by multiple actors over many years into novel technologies, vaccine, therapeutic and other products now available to address Covid-19 would not have occurred without the robust IP system in the EU and elsewhere. IP, particularly patents, has provided the legal framework and incentive for the high risk, high-cost investment underpinning the response to the pandemic.
Confindustria · filed 18 Jul 2023 · source
Confindustria contributed and agrees with BusinessEurope's position paper on European Commission proposal for mandatory authorization for the crisis management. Confindustria, in line with European industry, expresses strong concern about the EC proposal, which risks weakening the European patent law system to the detriment of innovation and competitiveness in the Eurozone
Confindustria · filed 1 Apr 2022 · source
A centralized system for the grant and enforcement of a Unitary SPC (“uSPC”) through a single procedure, analogously with what is being achieved with the European Patent with Unitary Effect and Unified Patent Court ( EP-UE and UPC, respectively) is certainly a very desirable option with a view to creating a more predictable, less burdensome and cost-effective system for Europe.
Leem · filed 5 Apr 2022 · source
Bringing new therapies to patients is a long, complex and risky process that requires long-term and continuous investments. Patents are critical to that purpose and to the EU’s innovation and industrial ambitions.
2 organizations on one sheet: every file each filed on, their register declarations, and a working link to each submission. Free: we ask for your name and email, and PolicySpeak may contact you about the product (privacy policy). The per-file record stays downloadable without signing up on each file’s page.